Loading
NASDAQHealthcareBiotechnology
Latest quote
$20.88
+$0.48 · +2.35%
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Previous close
$20.88
+$0.48 · +2.35%
Regular session · ET · Market data may be delayed.
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Day range
Current $20.88
52-week range
Current $20.88
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
58
Fair Value
Sentiment
55
Mixed
Risk
64
High Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Day range
Current $20.88
52-week range
Current $20.88
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10.84M USD | — | 10K USD | 75K USD | 1.16M USD |
| Gross profit | 10.84M USD | — | 10K USD | 75K USD | 1.16M USD |
| Research and development | 138.09M USD | 28.06M USD | 20.07M USD | 28.39M USD | 47.49M USD |
| Selling, general, and administrative | 25.39M USD | 16.32M USD | 19.21M USD | 19.09M USD | 17.12M USD |
| Operating expenses | 163.48M USD | 49.9M USD | 39.29M USD | 47.48M USD | 64.61M USD |
| Interest income | 2.88M USD | 1M USD | 2.38M USD | 714.52K USD | 19.77K USD |
| Interest expense | 2.19M USD | 852K USD | — | — | — |
| Depreciation and amortization | 84K USD | 35.17K USD | 153.3K USD | 207.15K USD | 264.6K USD |
| Operating income | −152.63M USD | −49.9M USD | −39.28M USD | −47.4M USD | −63.45M USD |
| Net income | −153.94M USD | −48.52M USD | −36.9M USD | −46.69M USD | −63.43M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$31.25
49.66% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 16, 2025 | 1:100 | — | — |
Effective Jun 16, 2025
1:100
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI13.12M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM9.54M0.01%79.88B USD0.19%$296.01+0.28%
iShares Russell 2000 Growth ETFIWO3.61M0.03%14.58B USD0.24%$377.54+0.12%
Vanguard Russell 2000 ETFVTWO1.76M0.01%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC1.31M0.09%1.47B USD0.60%$196.25+0.69%
Vanguard Extended Market ETFVXF1.21M0.00%93.7B USD0.05%$242.66+0.14%
Vanguard Health Care ETFVHT900.55K0.00%20.9B USD0.09%$321.66-0.97%
Virtus Biotech Clinical Trials ETFBBC357.06K0.70%50.31M USD0.65%$53.71+0.60%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Extended Market ETFVXFVanguard Health Care ETFVHTVirtus Biotech Clinical Trials ETFBBCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
